Ark Therapeutics Group plc is a gene-based medicine company with operations in the United Kingdom and Finland. The principal activity of the Company is the discovery, development and commercialization of products in areas of medicines, with particular focus on vascular disease and cancer. The Company had developed the drug-like small molecule antagonists of VEGF binding to neuropilin-1 receptors (NRP-1) and which in vivo show inhibition of tumour growth with associated anti-cancer activities of inhibiting the development of the tumour blood supply (anti-angiogenic) as well as directly impairing tumour cell growth and motility. It focuses on seeking development and commercialisation partners for its diverse product portfolio. Its biological manufacturing operations are based in Kuopio, Finland, and provide process development and manufacturing for internal programmes and those of third party clients for a variety of stages of therapeutic development.